Literature DB >> 8464405

Pathogenesis of human immunodeficiency virus infection.

J A Levy1.   

Abstract

The lentivirus human immunodeficiency virus (HIV) causes AIDS by interacting with a large number of different cells in the body and escaping the host immune response against it. HIV is transmitted primarily through blood and genital fluids and to newborn infants from infected mothers. The steps occurring in infection involve an interaction of HIV not only with the CD4 molecule on cells but also with other cellular receptors recently identified. Virus-cell fusion and HIV entry subsequently take place. Following virus infection, a variety of intracellular mechanisms determine the relative expression of viral regulatory and accessory genes leading to productive or latent infection. With CD4+ lymphocytes, HIV replication can cause syncytium formation and cell death; with other cells, such as macrophages, persistent infection can occur, creating reservoirs for the virus in many cells and tissues. HIV strains are highly heterogeneous, and certain biologic and serologic properties determined by specific genetic sequences can be linked to pathogenic pathways and resistance to the immune response. The host reaction against HIV, through neutralizing antibodies and particularly through strong cellular immune responses, can keep the virus suppressed for many years. Long-term survival appears to involve infection with a relatively low-virulence strain that remains sensitive to the immune response, particularly to control by CD8+ cell antiviral activity. Several therapeutic approaches have been attempted, and others are under investigation. Vaccine development has provided some encouraging results, but the observations indicate the major challenge of preventing infection by HIV. Ongoing research is necessary to find a solution to this devastating worldwide epidemic.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464405      PMCID: PMC372905          DOI: 10.1128/mr.57.1.183-289.1993

Source DB:  PubMed          Journal:  Microbiol Rev        ISSN: 0146-0749


  1282 in total

1.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.

Authors:  S Wain-Hobson; J P Vartanian; M Henry; N Chenciner; R Cheynier; S Delassus; L P Martins; M Sala; M T Nugeyre; D Guétard
Journal:  Science       Date:  1991-05-17       Impact factor: 47.728

2.  tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.

Authors:  F Wu; J Garcia; D Sigman; R Gaynor
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

3.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

Authors:  R J Orentas; J E Hildreth; E Obah; M Polydefkis; G E Smith; M L Clements; R F Siliciano
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

5.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

Review 6.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

7.  Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement.

Authors:  J Laurence; A Saunders; E Early; J E Salmon
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

8.  Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome.

Authors:  C Harris; C B Small; R S Klein; G H Friedland; B Moll; E E Emeson; I Spigland; N H Steigbigel
Journal:  N Engl J Med       Date:  1983-05-19       Impact factor: 91.245

9.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

10.  Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.

Authors:  S Pahwa; R Pahwa; C Saxinger; R C Gallo; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more
  248 in total

1.  Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments.

Authors:  F Manetti; F Corelli; N Mongelli; A L Borgia; M Botta
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

2.  HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Authors:  M Srivastava; M Cartas; T A Rizvi; S P Singh; D Serio; V S Kalyanaraman; H B Pollard; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure.

Authors:  Jonathan D Dinman; Sara Richter; Ewan P Plant; Ronald C Taylor; Amy B Hammell; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

5.  The anti-HIV pentameric pseudopeptide HB-19 is preferentially taken up in vivo by lymphoid organs where it forms a complex with nucleolin.

Authors:  B Krust; R Vienet; A Cardona; C Rougeot; E Jacotot; C Callebaut; G Guichard; J P Briand; J M Grognet; A G Hovanessian; L Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

7.  Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection.

Authors:  S G Kitchen; C H Uittenbogaart; J A Zack
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

8.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 9.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.